Infliximab 5 mg/kg and purine analogues vs purine analogues
Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.64 [1.31, 2.05]2 studies · 355 participantsModerate